PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2009 | 5 | 57-74
Article title

Marketing authorization of biosmimilar medical products

Authors
Title variants
Languages of publication
PL
Abstracts
EN
Biosimilars present a new category of products when compared with conventional generics. While the demonstration of a pharmacokinetic similarity is the main method to demonstrate therapeutic equivalence of generic medicinal products, a number of issues will make the approval of biosimilars more complicated. Therefore, the centralised procedure of marketing authorization is the only procedure allowed for these products in EU. New manufacturers will need to ensure that their biopharmaceutical has similar efficacy and safety profile to the reference product through more extensive clinical trials than the limited testing done for generic versions of low-molecular-weight chemical medicines. The primary issue of concern for the safety of these agents is the potential for immunogenicity. This review presents background information on the differences between biosimilars and low-molecular-weight generic drugs and the current regulatory situation, and provides information on the main sources of variability of biosimilars.
Keywords
Journal
Year
Issue
5
Pages
57-74
Physical description
Contributors
author
References
Document Type
MONOGRAPHY
Publication order reference
Waldemar Zielinski, Zaklad Farmakoekonomiki, Wydzial Farmaceutyczny, Warszawski Uniwersytet Medyczny, ul. Pawinskiego 3a, 02-106 Warszawa, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-674494bc-736e-3e89-8979-c21c91e2358b
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.